Table 2.
Vaccine efficacy against symptomatic COVID-19
| Study population | No. of events/Total No. |
Rate ratio |
Vaccine efficacy (95% CI)a | |
|---|---|---|---|---|
| SpikoGen® | Placebo | (95% CI) | ||
| Per-protocol | 247/9998 | 119/3069 | 0.56 (0.45–0.70) | 43.99 (30.30–55.00) |
| Per-protocol + nucleocapsid antibody–positive | 264/11 417 | 128/3502 | 0.56 (0.45–0.69) | 43.81 (30.61–54.51) |
| All participants | 266/11 760 | 128/3603 | 0.56 (0.45–0.69) | 44.22 (31.13–54.82) |
COVID-19, coronavirus disease 2019.
a
Vaccine efficacy and 95% CIs of the SpikoGen® in preventing COVID-19 in different populations with the use of Poisson regression with robust error variance.